Chronic Lymphocytic Leukemia (CLL) is the most common form of leukemia in the Western world. In the USA, 20,700 new cases are diagnosed each year, predominantly in older men. The disease is characterized by the overproduction of white blood cells called B lymphocytes, which normally play a role in protecting the body from infections. Over time, this overproduction leads to the accumulation of these cells in the bone marrow, lymph nodes, and spleen.
Many patients experience no symptoms for years, with the disease often discovered during routine blood tests that reveal elevated lymphocyte counts. However, as the disease progresses, it can cause symptoms such as swollen lymph nodes, an enlarged spleen, reduced bone marrow function (leading to decreased hemoglobin and platelets), recurrent infections, significant weight loss, and night sweats.
The course of the disease varies widely, ranging from cases requiring only long-term observation to more aggressive forms necessitating immediate treatment.
In recent years, a deeper understanding of the biology of CLL has revolutionized its treatment. Chemotherapy, once the standard, has been replaced by targeted biological therapies that selectively attack cancerous cells without harming healthy ones. These treatments are not only more effective but also have significantly fewer side effects, allowing patients to enjoy prolonged remission and a better quality of life.
Until recently, CLL treatments primarily fell into two categories:
BTK Inhibitors: These target the BTK enzyme, essential for the survival and proliferation of CLL cells. Current drugs irreversibly bind to the enzyme, but resistance often develops, rendering the treatment ineffective as the disease progresses.
BCL-2 Inhibitors: By inhibiting this protein, these drugs induce the death of CLL cells. In some cases, they are combined with antibodies targeting specific markers on CLL cells, enhancing the treatment's effectiveness. When one type of treatment fails, patients often transition to the other.
Until recently, patients whose disease advanced after these two lines of treatment faced poor prognoses, with life expectancy of less than six months and no viable options. This has now changed thanks to advancements in treatment.
One illustrative case involved a man with resistant CLL, severe lymph node swelling, and debilitating weakness. Despite previous treatments ceasing to work, a new therapy provided through his private insurance led to remarkable improvement. Within three weeks, he regained mobility, resumed daily activities, and no longer required blood transfusions. His blood counts normalized, and his quality of life significantly improved.
Clinical trials have introduced promising new BTK inhibitors that address resistance caused by mutations. Approved by the FDA, these drugs offer hope to patients who previously had no options. They provide a breakthrough by overcoming resistance mechanisms, reducing side effects, and maintaining a high quality of life.
These innovative therapies for advanced CLL are currently under review for inclusion in Israel's healthcare basket. Efforts must focus on making these treatments accessible to patients who have exhausted other options. By doing so, we can help extend their lives and allow them to create meaningful memories with loved ones while preserving their quality of life.
